Abstract
In a population with ongoing vaccination, the trajectory of a pandemic is determined by how the virus spreads in unvaccinated and vaccinated individuals that exhibit distinct transmission dynamics based on different levels of natural and vaccine-induced immunity. We developed a mathematical model that considers both subpopulations and immunity parameters including vaccination rates, vaccine effectiveness, and a gradual loss of protection. The model forecasted the spread of the SARS-CoV-2 delta variant in the US under varied transmission and vaccination rates. We further obtained the control reproduction number and conducted sensitivity analyses to determine how each parameter may affect virus transmission. Our results show that a combination of strengthening vaccine-induced immunity and preventative behavioral measures will likely be required to deaccelerate the rise of infectious SARS-CoV-2 variants.
One-Sentence Summary Mathematical models considering vaccinated and unvaccinated individuals help forecast and manage the spread of new SARS-CoV-2 variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ugo Avila Ponce de Leon also received a fellowship (CVU: 774988) from Consejo Nacional de Ciencia y Tecnologia (CONACYT). KH received funding from ISMMS and NIH NIGMS R35GM138113. This article was supported in part by Mexican SNI under CVU 15284.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was not required since the work used only publicly available data
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The original contributions presented in the study are included in the article/Supplementary Material. All code used for analysis is available https://github.com/UgoAvila/Delta-Variant-In-the-US.
